SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Ferdinando D'Amico  ¹     Giulia Palmieri  ¹     Arianna Dal Buono  ²     Roberto Gabbiadini  ²     Alessandro Armuzzi  ²     Bénédicte Caron  ³     Laurent Peyrin-Biroulet  ³     Paula Moreira  ⁴     Unknown Unknown  ⁵     Tommaso Innocenti  ⁶     Gabriele Dragoni  ⁶     Cristina Bezzio  ⁷     María Chaparro  ⁸     Javier Gisbert  ⁸     María José García  ⁹     Georgios Michalopoulos  ¹⁰     Nikos Viazis  ¹¹     Gerassimos J. Mantzaris  ¹¹     Pierre Ellul  ¹²     Silvio Danese  ¹²     Gionata Fiorino  ¹²     Mariangela Allocca  ^12    
1 IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
² IRCCS Humanitas Research Hospital, Rozzano, Italy
³ University of Lorraine, Nancy, France
⁴ Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
⁵ Hospital Clínico Universitario de Valencia, Valencia, Spain
⁶ Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
⁷ Rho Hospital, ASST Rhodense, Milan, Italy
⁸ Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Sp
⁹ Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain
¹⁰ General Hospital of Athens "G. Gennimatas", Athens, Greece
¹¹ ‘Evangelismos-Polykliniki’ GHA, Athens, Greece
¹² Mater Dei Hospital, Msida, Malta

Topic
IBD

Session
The switch game: Optimal treatment modalities in IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)